We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+12.67%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$701M
AUM Growth
+$112M
Cap. Flow
+$80.1M
Cap. Flow %
11.43%
Top 10 Hldgs %
45.26%
Holding
159
New
30
Increased
40
Reduced
26
Closed
28

Top Buys

Rank Stock Value
1
CEL
Cellcom Israel, Ltd.
CEL
+$14.1M
2
AGN
Allergan plc
AGN
+$14M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$9M
4
MRK icon
Merck
MRK
+$6.67M
5
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$6.17M

Top Sells

Rank Stock Value
1
NVS icon
Novartis
NVS
+$16M
2
BMY icon
Bristol-Myers Squibb
BMY
+$13.8M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$12.2M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$3.99M
5
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$3.63M

Sector Composition

Rank Sector Weight
1 Healthcare 62.92%
2 Technology 5.67%
3 Communication Services 2.64%
4 Industrials 1.06%
5 Financials 1.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DCOY
76
Decoy Therapeutics
DCOY
$2.19M
– –
0
– –
ORCL icon
77
Oracle
ORCL
$374B
$2.29M 0.33%
47,250
– –
ALBO
78
DELISTED
Albireo Pharma Inc
ALBO
$2.27M 0.32%
108,526
+5,000
+5% +$119K
CTSH icon
79
Cognizant
CTSH
$24.9B
$2.24M 0.32%
+30,866
New +$2.17M
ORLY icon
80
CALL
O'Reilly Automotive
ORLY
$72.9B
$2.15M 0.31%
150,000
+148,500
+9,900% +$1.96M
OBSV
81
DELISTED
ObsEva SA Ordinary Shares
OBSV
$2.12M 0.3%
260,197
+28,700
+12% +$218K
AAP icon
82
CALL
Advance Auto Parts
AAP
$3.35B
$2.08M 0.3%
21,000
+20,750
+8,300% +$2.09M
SIOX
83
PUT
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$2.06M 0.29%
+37,500
New +$6.33M
TXMD icon
84
TherapeuticsMD
TXMD
$23.5M
$2.01M 0.29%
7,600
-4,000
-34% -$1.16M
ARDX icon
85
Ardelyx
ARDX
$1.22B
$1.93M 0.28%
345,000
– –
EVOK
86
DELISTED
Evoke Pharma
EVOK
$1.91M 0.27%
3,965
+493
+14% +$190K
DOVA
87
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
$1.9M 0.27%
78,284
-16,716
-18% -$396K
VTVT icon
88
vTv Therapeutics
VTVT
$127M
$1.79M 0.26%
7,500
– –
NITE
89
DELISTED
Nightstar Therapeutics plc American Depositary Shares
NITE
$1.73M 0.25%
+90,000
New +$1.94M
VTGN icon
90
VistaGen Therapeutics
VTGN
$9.89M
$1.69M 0.24%
35,280
+17,143
+95% +$903K
RNTX
91
Rein Therapeutics
RNTX
$63.1M
$1.67M 0.24%
6,250
– –
FPRX
92
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$1.64M 0.23%
+40,000
New +$1.26M
MA icon
93
Mastercard
MA
$506B
$1.63M 0.23%
11,525
– –
CYTK icon
94
CALL
Cytokinetics
CYTK
$10.5B
$1.45M 0.21%
+100,000
New +$1.37M
DCPH
95
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$1.42M 0.2%
+75,000
New +$1.37M
ACHN
96
DELISTED
Achillion Pharmaceuticals
ACHN
$1.35M 0.19%
+300,000
New +$1.33M
TEVA icon
97
PUT
Teva Pharmaceuticals
TEVA
$40.8B
$1.27M 0.18%
72,000
+70,880
+6,329% +$1.59M
SIOX
98
CALL
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$1.24M 0.18%
+22,500
New +$3.8M
SNA icon
99
Snap-on
SNA
$21.2B
$1.09M 0.16%
7,292
-8,505
-54% -$1.28M
NGNE icon
100
Neurogene
NGNE
$656M
$1.07M 0.15%
3,777
+673
+22% +$193K
2 3
4
5 6

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q3 2017 Portfolio in Review

As of Q3 2017, Sphera Funds Management held 159 positions worth $701M, up 19% from $589M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sphera Funds Management deployed $80.1M of net new capital in Q3 2017, opening 30 new positions and adding to 40 existing holdings. Its largest new stake was Cellcom Israel, Ltd.: 1,535,988 shares worth $14.3M.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 66% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Caesarstone, an estimated $3.28M trimmed.

  • Sphera Funds Management's largest Q3 2017 buy was Cellcom Israel, Ltd.: 1,535,988 shares worth $14.3M.
  • Sphera Funds Management added most to Merck in Q3 2017, an estimated $6.67M increase.
  • Sphera Funds Management's biggest Q3 2017 reduction was Caesarstone, cutting an estimated $3.28M.
  • Sphera Funds Management fully exited Novartis in Q3 2017, selling an estimated $16M.
  • Sphera Funds Management's ten largest holdings make up 45% of its $701M portfolio in Q3 2017.
  • Sphera Funds Management opened 30 new positions and closed 28 in Q3 2017.
  • Sphera Funds Management's portfolio value rose 19% quarter-over-quarter to $701M.

Based on Sphera Funds Management's 13F filing for Q3 2017, filed 9 Nov 2017.